---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-23-000382"
form_type: "8-K"
ticker: "LIPO"
cik: "0001347242"
company_name: "LIPELLA PHARMACEUTICALS INC."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T06:50:32.820061+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lipella completes Phase 2a trial of LP-10 for hemorrhagic cystitis; reports $5.1M cash, IPO completed

## Summary
- Completed Phase 2a trial of LP-10 for hemorrhagic cystitis; top-line results showed no serious adverse events and reduced symptoms.
- Year-end cash $5.1M, provides operating runway into 2024.
- Appointed Douglas Johnston as CFO in November 2022.
- Completed IPO and Nasdaq listing in December 2022.
- Created Oral Health Scientific Advisory Board for LP-310; results to be presented at AUA meeting April 30, 2023.

## SEC filing metadata
- accession: 0001753926-23-000382
- form_type: 8-K
- ticker: LIPO
- cik: 0001347242
- company_name: LIPELLA PHARMACEUTICALS INC.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347242/000175392623000382/0001753926-23-000382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347242/000175392623000382/g083471_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-23-000382
- JSON: https://secwatch.observer/filing/0001753926-23-000382.json
- Plain text: https://secwatch.observer/filing/0001753926-23-000382.txt

## Key facts
- Earnings Releases
  LIPELLA PHARMACEUTICALS INC. reported financial results for the fiscal year ended December 31, 2022.
  - Period: the fiscal year ended December 31, 2022
  - Result: reported results
  source text: today provided a business update and reported financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347242/000175392623000382/0001753926-23-000382-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.